These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 9858218)
1. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Liu ES; Burian C; Miller WE; Saven A Br J Haematol; 1998 Dec; 103(3):690-5. PubMed ID: 9858218 [TBL] [Abstract][Full Text] [Related]
2. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Betticher DC; Hsu Schmitz SF; Ratschiller D; von Rohr A; Egger T; Pugin P; Stalder M; Hess U; Fey MF; Cerny T Br J Haematol; 1997 Nov; 99(2):358-63. PubMed ID: 9375754 [TBL] [Abstract][Full Text] [Related]
3. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453 [TBL] [Abstract][Full Text] [Related]
5. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Laurencet FM; Zulian GB; Guetty-Alberto M; Iten PA; Betticher DC; Alberto P Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762 [TBL] [Abstract][Full Text] [Related]
6. Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. Takamatsu Y; Suzumiya J; Ogata K; Katayose K; Sasaki H; Ishitsuka K; Kimura N; Tamura K J Clin Exp Hematop; 2009 Nov; 49(2):69-75. PubMed ID: 19907111 [TBL] [Abstract][Full Text] [Related]
7. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia. Tetreault SA; Saven A Leuk Lymphoma; 2000 Mar; 37(1-2):125-30. PubMed ID: 10721776 [TBL] [Abstract][Full Text] [Related]
8. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437 [TBL] [Abstract][Full Text] [Related]
9. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Dimopoulos MA; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating MJ; Freireich EJ; Alexanian R Ann Intern Med; 1993 Feb; 118(3):195-8. PubMed ID: 8093333 [TBL] [Abstract][Full Text] [Related]
11. Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients. Karlsson K; Strömberg M; Liliemark J; Delannoy A; Johnson SA; Porwit A; Kimby E; Lärfars G; Cristiansen I; Nilsson G; Celsing F; Sundström G; Luthman M; Tidefelt U; Wallvik J; Juliusson G Br J Haematol; 2002 Mar; 116(3):538-48. PubMed ID: 11849209 [TBL] [Abstract][Full Text] [Related]
12. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165 [TBL] [Abstract][Full Text] [Related]
13. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma. Fridrik MA; Jäger G; Kienzer HR; Hausmaninger H; Oppitz P; Krieger O; Zabernigg A; Lang A; Neubauer M; Weidinger G; Schiller L; Seewann HL; Chott A; Linkesch W Eur J Cancer; 1998 Sep; 34(10):1560-4. PubMed ID: 9893628 [TBL] [Abstract][Full Text] [Related]
15. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330 [TBL] [Abstract][Full Text] [Related]
17. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia. Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213 [TBL] [Abstract][Full Text] [Related]
18. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145 [TBL] [Abstract][Full Text] [Related]
20. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. Saven A; Lee T; Schlutz M; Jacobs A; Ellison D; Longmire R; Piro L J Clin Oncol; 1997 Jan; 15(1):37-43. PubMed ID: 8996122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]